J&J probes possible Crucell contamination; Hikma aims to use $500M war chest;

@FiercePharma: Drugmakers rack up $1B in small deals. Article | Follow @FiercePharma

> Johnson & Johnson is looking into possible contamination issues at a South Korean drug facility owned by a company that the American healthcare giant is acquiring. Story

> Hikma Pharmaceuticals, which has just bought Baxter International's U.S. drugs unit, has another $500 million war chest to spend on yet more acquisitions. Article

> Canadian health authorities say GlaxoSmithKline is recalling one lot of Emo-Cort skin lotion because of mold contamination and has halted manufacturing of all Emo-Cort products pending an investigation into the cause. News

> Bayer's blood thinner Xarelto matched the standard therapy at preventing blood clots in patients with an irregular heartbeat, results that may determine its success in a market worth as much as $14 billion. Story

> Pfizer topped the list of America's most generous companies in 2009, according to The Chronicle of Philanthropy, with gifts of cash and products valued at $2.3 billion. Report

> Forest Laboratories won approval Teflaro, a treatment for drug-resistant infections that kill tens of thousands of Americans every year. Story

> The FDA has approved Novartis' Afinitor to treat benign brain tumors. Article

> Astellas Pharma cut its full-year profit forecast a second time, saying earnings will be 13 percent less than predicted because of costs relating to its $4 billion takeover of OSI Pharmaceuticals. Report

> Sun Pharmaceutical Industries, India's biggest drugmaker by market value, said second-quarter profit rose 12 percent on higher demand for generic medicines. Report

> Acorda Therapeutics posted its first quarterly profit in at least three years, surprising Wall Street analysts, on continued robust sales of its key drug Ampyra. Item

Biotech News

 @FierceBiotech: Next-gen biotechs pursue 'undruggable' targets. Story | Follow @FierceBiotech

 @JohnCFierce: Had a fine time in Boston talking clinical trials with Sanofi, AstraZeneca, Aveo and Cubist Wednesday. Followed up with finance panel in DC Thursday. | Follow @JohnCFierce

> Roche prepares its counterattack against biosimilars. Story

> Waksal making big development plans for his new biotech venture. Article  

> Biodel shares plunge after FDA demands two new Ph3 trials. Report 

> In bombshell, DOJ reverses stance on gene patents. Item 

> Will Avanir drug OK spark takeover attempt? Story

> GSK inks $231M pact for Ph3 Amicus drug. Article

Biotech IT News

> Site provides trial matches, forum for diabetics. Report

> EDC gets cool reception in the clinic. News

> Ovum analyst sees analytics boost in Oracle CDA 2.0. Item

> HHS counts 200 data breaches. Article

>  FDA creates IT shopping list for makeover. Story 

And Finally... Fifty years after the pill, another birth control revolution may be on the horizon: free contraception for women in the U.S., thanks to the new healthcare law. News

Suggested Articles

The FDA is bracing for drug and medical supply shortages in the U.S. as the COVID-19 outbreak from China continues to spread globally.

Astellas and Seattle Genetics are out with Padcev-Keytruda combo data that may be good enough to snag an expedited regulatory review, analysts say.

Distributors had offered billions of dollars to wrap up opioid litigation, but that effort has suffered a major setback, WSJ reports.